# Pazopanib and ARQ 197 for Advanced Solid Tumors

> **NCT01468922** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 32 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** ARQ 197

## Key facts

- **NCT ID:** NCT01468922
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-23
- **Primary completion:** 2014-09-30
- **Final completion:** 2016-02-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01468922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01468922, "Pazopanib and ARQ 197 for Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01468922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*